- Home
- ANIX vs ANL Comparison
ANIX vs ANL Comparison
Compare ANIX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- ANL
- Stock Information
- Founded
- ANIX 1982
- ANL 2004
- Country
- ANIX United States
- ANL Cayman Islands
- Employees
- ANIX N/A
- ANL N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- ANIX Health Care
- ANL
- Exchange
- ANIX Nasdaq
- ANL Nasdaq
- Market Cap
- ANIX 84.7M
- ANL 73.8M
- IPO Year
- ANIX 1987
- ANL 2023
- Fundamental
- Price
- ANIX $2.93
- ANL $1.77
- Analyst Decision
- ANIX Strong Buy
- ANL Strong Buy
- Analyst Count
- ANIX 3
- ANL 2
- Target Price
- ANIX $9.00
- ANL $9.00
- AVG Volume (30 Days)
- ANIX 42.2K
- ANL 10.1K
- Earning Date
- ANIX 06-10-2025
- ANL 06-10-2025
- Dividend Yield
- ANIX N/A
- ANL N/A
- EPS Growth
- ANIX N/A
- ANL N/A
- EPS
- ANIX N/A
- ANL N/A
- Revenue
- ANIX N/A
- ANL N/A
- Revenue This Year
- ANIX N/A
- ANL N/A
- Revenue Next Year
- ANIX N/A
- ANL N/A
- P/E Ratio
- ANIX N/A
- ANL N/A
- Revenue Growth
- ANIX N/A
- ANL N/A
- 52 Week Low
- ANIX $2.07
- ANL $1.10
- 52 Week High
- ANIX $4.20
- ANL $8.88
- Technical
- Relative Strength Index (RSI)
- ANIX 63.69
- ANL 42.48
- Support Level
- ANIX $2.50
- ANL $1.71
- Resistance Level
- ANIX $2.72
- ANL $2.10
- Average True Range (ATR)
- ANIX 0.15
- ANL 0.08
- MACD
- ANIX 0.03
- ANL 0.00
- Stochastic Oscillator
- ANIX 97.96
- ANL 0.00
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.